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Abstract 
Background: Levels of both angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) correlate with malaria disease sever-
ity and are proposed as biomarkers and possible therapeutic targets. To establish their role in malaria, a systematic 
review was performed of the literature on Ang-1 and Ang-2 with regard to their potential as biomarkers in malaria 
and discuss their possible place in adjuvant treatment regimens.
Methods: Ten electronic databases were systematically searched to identify studies investigating Ang-1 and Ang-2 
in human and murine malaria in both clinical and experimental settings. Information about the predictive value of 
Ang-1 and Ang-2 for disease severity and their regulatory changes in interventional studies were extracted.
Results: Some 579 studies were screened; 26 were included for analysis. In all five studies that determined Ang-1 
levels and in all 11 studies that determined Ang-2 in different disease severity states in falciparum malaria, a decline 
in Ang-1 and an increase of Ang-2 levels was associated with increasing disease severity. All nine studies that deter-
mined angiopoietin levels in Plasmodium falciparum patients to study their ability as biomarkers could distinguish 
between multiple disease severity states; the more the disease severity states differed, the better they could be 
distinguished. Five studies differentiating malaria survivors from non-survivors with Ang-2 as marker found an AUROC 
in a range of 0.71–0.83, which performed as well or better than lactate. Prophylactic administration of FTY720, rosigli-
tazone or inhalation of nitric oxide (NO) during malaria disease in mice resulted in an increase in Ang-1, a decrease in 
Ang-2 and an increased survival. For rosiglitazone, a decrease in Ang-2/Ang-1 ratio was observed after post-infection 
treatment in mice and humans with malaria, but for inhalation of NO, an effect on Ang-1 and survival was only 
observed in mice.
Conclusion: Both Ang-1 and Ang-2 levels correlate with and can distinguish between malaria disease severity states 
within the group of malaria-infected patients. However, distinct comparisons of disease severity states were made in 
distinct studies and not all distinctions made had clinical relevance. Changes in levels of Ang-1 and Ang-2 might also 
reflect treatment effectiveness and are promising therapeutic targets as part of multi-targeted therapy.
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Background
General aspects of malaria and endothelial cell activation
Even though many disease control interventions have 
been implemented, malaria remains a major health prob-
lem with an estimated 214 million cases and 438,000 
deaths worldwide in 2015 [1]. Most of these malaria 
deaths were caused by Plasmodium falciparum, one of 
the six Plasmodium species (Plasmodium cynomolgi, 
P. falciparum, Plasmodium knowlesi, Plasmodium 
malariae, Plasmodium ovale, Plasmodium vivax) that 
can infect humans. The high pathogenicity of P. falci-
parum is in part related to the expression of P. falcipa-
rum erythrocyte membrane protein-1 (PfEMP-1) on 
the membranes of infected erythrocytes. The infected 
erythrocytes with PfEMP-1 on the membrane adhere to 
the vascular endothelium of vital organs. This process is 
called sequestration and will cause a partial obstruction 
of the blood flow. Together with the increased deform-
ability of uninfected erythrocytes and adherence of unin-
fected erythrocytes to infected erythrocytes, which is 
called rosetting [2], extensive sequestration will lead to a 
decline in oxygen delivery to the organs. Without treat-
ment, the lack of oxygen will result in acidosis and multi-
organ failure, along with endothelial barrier dysfunction 
and inflammation. This may eventually lead to death in 
untreated cases, especially in non-immune individuals. 
Of the non-falciparum species, P. vivax, which may run 
a relatively benign course compared to P. falciparum, is 
most important and can also cause severe malaria and 
result in death. The pathogenesis of P. vivax infection dif-
fers from P. falciparum infection and is still poorly under-
stood. Plasmodium vivax infects only young erythrocytes 
(reticulocytes) which can also adhere to the vascular 
endothelium, but showed ten times less cyto-adhesion 
compared to P. falciparum-infected erythrocytes in vitro 
[3]. Also, the cytokine response differs between the spe-
cies: P. vivax showed a stronger response than P. falci-
parum [4]. Whether cyto-adherence in P. vivax leads to 
disproportional organ-specific parasitaemia and what 
role the cytokine response plays in the pathogenesis 
remains unclear.
Endothelial cell activation
Endothelial cell activation is crucial in the pathogenesis 
of P. falciparum infection as PfEMP-1 on the erythro-
cyte membranes interacts with several cyto-adherence 
receptors that show a low, basal expression pattern in 
a non-inflammatory environment, but are upregulated 
during malaria infection [5]. Activation of endothelial 
cells is complex and interconnected with other pro-
cesses, such as coagulation and inflammation. Quies-
cent endothelial cells have anticoagulant properties due 
to expression of several proteins, such as protein C and 
thrombomodulin. On the other hand, after activation 
by, e.g., thrombin [6], fibrin [7, 8], complement factors 
C5–C9 [9], or platelets [10], endothelial cells express or 
release procoagulant and inflammatory proteins, such 
as tissue factor, von Willebrand factor (vWF), Ang-
2, I-CAM, V-CAM, and E-selectin [5, 11]. Endothelial 
cell activation occurs not only during malaria but also 
during many other infectious diseases, such as bacterial 
sepsis [12] and dengue haemorrhagic fever [13, 14]. To 
study endothelial cell activation during infectious dis-
eases, expression levels of multiple endothelial-cell acti-
vation markers have been determined and were found 
to be increased, including the vascular growth factors 
Ang-1 and Ang-2, which were extensively studied dur-
ing systemic inflammation (reviewed in [15–20]). Their 
role in endothelial cell activation during malaria has 
also been investigated.
Ang‑1, Ang‑2 and endothelial cell activation
Ang-1 and Ang-2 are ligands of the Tie-2 receptor, which 
is expressed on endothelial cells and regulates endothe-
lial quiescence during normal physiological conditions. 
Ang-1 is constitutively produced and excreted into the 
blood by pericytes and smooth muscle cells and it is also 
stored in platelets. Ang-1 binds to the Tie-2 receptor, 
thereby acting as an agonist. Upon Ang-1/Tie-2 interac-
tion, the most important downstream signalling event is 
protein kinase B phosphorylation by phosphoinositide-
3-kinase resulting in an anti-apoptotic and anti-inflam-
matory status of the endothelial cell.
Ang-2 is produced in endothelial cells and pre-stored 
in the Weibel–Palade bodies (WPB) together with vWF. 
Upon activation of endothelial cells, exocytosis of the 
WPB is induced and their content is released into the 
blood stream [21]. The increased Ang-2/Ang-1 ratio 
causes a replacement of the Ang-1-Tie-2 interaction by 
an Ang-2-Tie-2 interaction. In the presence of Ang-1, 
Ang-2 acts as a functional antagonist and the Ang-2-
Tie-2 interaction results in the blocking of the protective, 
anti-inflammatory and anti-apoptotic effect of Ang-1 
(Fig.  1). Therefore, Ang-2 release and binding to Tie-2 
receptors further stimulates the inflammatory response 
of endothelial cells. However, an agonistic function of 
Ang-2 has also been described and is influenced by cell 
type and experimental conditions [22]. A decrease in 
the Ang-1 concentration during pro-inflammatory con-
ditions, also contributes to the increased Ang-2/Ang-1 
ratio. The underlying mechanisms of the Ang-1 decrease 
have not been defined yet. From these findings, it may be 
hypothesized that the role of Ang-1 is protective during 
malaria and the role of Ang-2 may be harmful.
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Ang‑1 and Ang‑2 are likely to play a role early in malaria 
pathogenesis
During malaria, a decrease in Ang-1 and an increase in 
Ang-2 concentration have been observed [15]. It is not 
known whether the decrease of Ang-1 and increase of 
Ang-2 are the result of the endothelium activation status 
or that the altered levels also contribute to endothelium 
activation. However, during the initial processes that lead 
to pathology in malaria, Ang-1 and Ang-2 might play a 
role as (1) Ang-1 and Ang-2 levels strongly correlate with 
disease severity and mortality [15]; (2) in sepsis, which 
shares many similarities with severe malaria [15, 18, 23], 
interfering in the angiopoietin-Tie-2 system, had a huge 
effect on the inflammatory response, vascular leakage 
and survival [24]; and, (3) Ang-2 can be released rapidly 
upon activation of endothelial cells as it is pre-stored in 
WPBs [21]. After exocytosis of WPBs, released Ang-2 
may then have extended effects in further activation of 
endothelial cells by activation of a pro-inflammatory 
amplification loop.
Because of the correlation of Ang-1 and Ang-2 levels 
with disease severity and mortality, Ang-1 and Ang-2 
have been evaluated as biomarkers for malaria disease 
severity in multiple studies. However, each individual 
study compared different disease severity states and the 
studies were performed in distinct populations at dif-
ferent geographical locations around the world. To gain 
more insight in their role during malaria, the current 
literature concerning the use of Ang-1 and Ang-2 as 
biomarker in a clinical setting is here reviewed systemati-
cally. Furthermore, the role of Ang-1 and Ang-2 as poten-
tial therapeutic targets in malaria is evaluated as they 
might play a causative role in the pathogenesis.
Methods
Literature search and inclusion criteria
A broad systematic literature-search strategy was created 
combining synonyms for angiopoietin with synonyms for 
malaria or Plasmodium. In Embase, Medline and CInahl, 
thesaurus terms were used together with words in title 
and/or abstract. In the other databases only titles and/
or abstracts were searched. The databases Embase.com, 
Medline (Ovid), Cochrane Central registry of trials, Web 
of Science, Scopus, cinahl (EBSCOhost), Pubmed as sup-
plied by publisher (for the most recent, not yet indexed, 
articles), lilacs, scielo, ProQuest, and Google scholar (an 
additional search), were searched without data limit, 
from inception lastly on 15 June 2016 (see Additional 
file  1). Based on the titles and abstracts, potentially rel-
evant articles were selected by two independent review-
ers (GMdJ, JJS) for full text screening. Articles in English 
meeting the inclusion criteria were included (see Addi-
tional file 2). In case of disagreement between the review-
ers, a third independent reviewer was consulted (JJvH).
Reported studies were included if Ang-1 and/or Ang-2 
protein or mRNA levels were determined in any speci-
men in humans and/or mice with a confirmed Plasmo-
dium infection. Through tracking the citations in selected 
articles, no additional articles were found.
Data extraction
The selected articles were grouped, depending on the 
study aim, into: (I) studies performed in non-pregnant 
humans; and, (II) interventional studies. The aim of stud-
ies in I was to correlate Ang-1 and Ang-2 levels with dis-
ease severity and in II to find an adjuvant therapy next to 
anti-malarial treatment.
Fig. 1 Schematic overview of function and localisation of Ang-1, Ang-2 and the Tie-2 receptor. Ang-2 is pre-stored in the Weibel–Palade bodies in 
endothelial cells and is released upon endothelial cell activation. Ang-2 replaces Ang-1 by binding the Tie-2 receptor, preventing its activation and 
thereby blocking the anti-inflammatory, anti-apoptotic and tight-junction supporting effects of Ang-1. Ang-1, angiopoietin-1; Ang-2, angiopoi-
etin-2; ICAM-1, E-selectin, VCAM-1, adhesion molecules; PfEMP-1, P. falciparum erythrocyte membrane protein 1; WPB, Weibel–Palade body
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For the articles of I, information was extracted on the 
Plasmodium species, the study population, the Ang-1 
and/or Ang-2 protein and/or mRNA levels or the Ang-2/
Ang-1 ratio in various disease states, and information 
about the associations of Ang-1 and Ang-2 levels with 
other variables. In the studies included in II, data were 
extracted regarding study subject, mice species or popu-
lation characteristics, details of the studied intervention, 




Twenty-six studies assessing Ang-1 and/or Ang-2 pro-
tein and/or mRNA levels in human and/or mice with a 
confirmed Plasmodium infection were identified and 
included for analysis; 22 studies were performed in 
humans only, of which five included children and adults 
in Asia and Canada as a single group (see Additional 
file  3), six studies included adults only and were per-
formed in Asia and Brazil (see Additional file  4), eight 
studies included children only and were all performed 
in only African countries (see Additional file 5) and one 
study included a separate group of children and adult [25] 
(see Additional files 4, 5). Three studies provided data 
on mice only (see Additional file  6). One interventional 
study combined results of studies in mice and humans 
[26] (see Additional file 6).
In nine studies a discriminative value of Ang-1, Ang-2 
levels or the Ang-2/Ang-1 ratio for disease severity was 
reported [25, 27–35] (see Additional file 7). Four studies 
determined the Ang-1 and/or the Ang-2 level in humans 
after start of anti-malarial treatment [29, 34, 36, 37]. 
Three studies investigated the effect of adjuvant therapy 
next to standard treatment on survival and on Ang-1 
and/or Ang-2 levels in mice [38–40], two in humans [41, 
42] and one in both humans and mice [26] during Plas-
modium species infection (see Additional file  6). One 
study used a mouse model with one deleted Ang-1 allele 
[26] (see Additional file 6).
Aim I: Ang‑1 and Ang‑2 levels as biomarkers for malaria 
disease severity
Ang‑1 is decreased and Ang‑2 is increased 
during Plasmodium species infection in non‑pregnant 
humans
In ten out of eleven studies comparing healthy con-
trols with either uncomplicated [25, 32, 34, 35, 37, 43–
45], severe [34, 35, 43, 45, 46] or cerebral falciparum 
malaria [25, 32, 37, 44, 45] or uncomplicated [43, 47] or 
severe [43] vivax malaria, a similar pattern in changes 
was observed for Ang-1 and Ang-2 levels: a decrease 
of Ang-1 [25, 32], an increase of Ang-2 [25, 32, 34, 35, 
37, 43–47] and consequently an increase of the Ang-2/
Ang-1 ratio [25, 32] (see Additional files 3, 4, 5). Adults 
and children, living either in endemic areas or travellers 
in non-endemic areas all showed these similar changes. 
However, one study [36] out of three [25, 32, 36] that 
determined the Ang-1 levels in falciparum malaria found 
an increase in Ang-1 compared with the levels in healthy 
controls opposed to a decline in the other studies. The 
absolute concentration of Ang-2 was significantly higher 
in P. vivax-infected patients compared to P. falcipa-
rum-infected patients in Indonesia, independent of the 
observed peripheral parasitaemia [47]. Contrastingly, a 
significant lower Ang-2 concentration was observed in 
P. vivax- compared to P. falciparum-infected travellers in 
Canada [48]. Barber et al. [43] determined also the Ang-2 
levels in both uncomplicated vivax malaria [median pg/
ml (IQR)] [4557 (3463–6197)] and falciparum malaria 
[3230 (2123–5243)] and in severe vivax malaria [8857 
(6547–9734)] and falciparum malaria [8371 (3963–
13,463)]. However, this study did not statistically com-
pare the levels between the vivax and falciparum malaria, 
although Ang-2 seems to be higher in P. vivax-infected 
patients especially when the higher parasitaemia of P. fal-
ciparum-infected patients was taken into account.
Differences in the absolute Ang-1 and Ang-2 concen-
trations were also found between disease severity states: 
lower Ang-1 and higher Ang-2 concentrations were 
observed in severe disease compared to uncomplicated 
disease in both falciparum [25, 28–30, 32, 34, 43–45] and 
vivax malaria [31, 43] and in non-survivors compared to 
survivors infected with P. falciparum [25, 27, 30, 32–35, 
41, 46] (see Additional files 3, 4, 5, 6).
Furthermore, an elevated Ang-2 concentration was 
associated with respiratory distress [49], impaired con-
sciousness [49], acute kidney injury [33, 46], multi-organ 
failure [46], anaemia [33], jaundice [33], hypoglycaemia 
[33], pure cerebral malaria (cerebral malaria patients 
without the other complications of severe malaria 
according to WHO 2000 criteria) [33] and higher Ang-1 
levels were associated with a higher platelet count in P. 
falciparum and P. vivax infections [31, 33, 50].
Ang‑1 increases and Ang‑2 decreases after start 
of anti‑malarial treatment in survivors
An increase in Ang-1 and a decrease in Ang-2 levels in 
survivors compared to non-survivors was observed after 
the start of treatment in both children [29] and adults 
[34, 36] (see Additional files 3, 4, 5) and one study found 
an average Ang-2 decrease of 2.7  ng/ml over a 24-hour 
period in survivors [34]. Moxon et al. [37] found a nearly 
two-fold decline in Ang-2 level in children with uncom-
plicated malaria and a five-fold decline in children with 
severe malaria 28  days after the start of treatment. 
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However, 28  days after treatment, the Ang-2 levels in 
uncomplicated malaria were still significant higher than 
Ang-2 levels in healthy controls. This lack of decrease 
to baseline levels might be caused by a 50% loss to fol-
low-up, which may have led to a biased difference in 
Ang-2 value between healthy control and patients after 
treatment.
Ang‑1 and Ang‑2 levels have a varying discriminative power 
for distinguishing disease severity states in humans
Uncomplicated falciparum malaria can rapidly pro-
gress into life-threatening disease due to the exponential 
increase in parasite biomass and sequestration of infected 
erythrocytes, which may lead to organ failure. The cur-
rently used biomarkers for disease severity have a limited 
predictive value to identify those patients that will rap-
idly progress towards complicated disease [51]. Several 
new markers have been proposed and investigated [52] 
as prognostic parameters for severe malaria, including 
Ang-1 and Ang-2. In distinct studies Ang-1, Ang-2 and 
the Ang-2/Ang-1 ratio were used to investigate whether 
they could distinguish different disease severity states 
and survivors from non-survivors [25, 27–35] (see Addi-
tional file 7).
The Ang-1 concentration was found to be the best dis-
criminator between uncomplicated malaria and severe 
malaria [28] with a sensitivity of 86% (95% CI 71–94) 
and a specificity of 85% (95% CI 76–92) (see Additional 
file 7). As expected, the more the disease severity states 
reflected both ends of the spectrum (e.g., uncomplicated 
malaria versus cerebral malaria) the better they could be 
distinguished [25, 28, 29, 32] (see Additional file 7).
Since cerebral malaria is a complication of falciparum 
malaria and therefore a manifestation of severe malaria, 
distinguishing cerebral malaria from other forms of 
severe malaria was difficult, as shown by the observa-
tion that only the Ang-1 concentration had a predictive 
value significantly higher than chance [28] with a sensi-
tivity of 72% (95% CI 56–84) and specificity of 66% (95% 
CI 55–75). The predictive value of the Ang-2 concentra-
tion for fatal outcome was found to be as well as plasma 
lactate in Vietnamese adults with severe malaria [33] 
and in Malawian children with cerebral malaria [27], and 
even better in Indonesian adults with severe malaria [34] 
(see Additional file 7). In order to increase the discrimi-
native power, two studies used a combination of mark-
ers [27, 30]. Incorporating the Ang-2 concentration or 
the Ang-1, Ang-2 and Tie-2 concentrations in a clinical 
model, comprising age, body condition score, respiratory 
distress, and severe anaemia as other parameters, signifi-
cantly improved the ability to accurately predict survival 
or fatal outcome compared to the clinical model alone 
(c-index (95% CI), p value) (i: 0.78 (0.68–0.82), 0.02; ii: 
0.79 (0.72–0.84), 0.03) [27]. The combination of Ang-2 
with CXCL10 and sICAM-1 had a sensitivity of 100% and 
a specificity of 93% to distinguish survivors from non-
survivors) [30].
In addition to the use as biomarker for disease severity 
in humans infected with Plasmodium species, the Ang-1 
and Ang-2 concentration may also be used for distin-
guishing cerebral malaria from other diseases involving 
the central nervous system (CNS) in critically ill patients. 
Distinguishing cerebral malaria from other febrile dis-
eases affecting the CNS is challenging, but can have 
major treatment implications. Ang-1 was found to differ-
entiate between cerebral malaria, diagnosed by malaria 
specific retinopathy, and other febrile CNS-affecting 
diseases with a sensitivity and specificity of 88% (95% CI 
69–96) and 87% (95% CI 73–94), respectively (see Addi-
tional file 7) [29].
Ang‑1 and Ang‑2 levels do not correlate with parasitaemia, 
sequestration and erythrocyte rosetting
Assuming that Ang-1 and Ang-2 concentrations and par-
asitaemia, parasite biomass, sequestration, and erythro-
cyte rosetting all reflect disease severity during malaria, 
a tight correlation between them may be anticipated. 
However, no correlation was found between concentra-
tions of Ang-1 and Ang-2 or Ang-2/Ang-1 ratio and 
sequestration in cerebral malaria in brain autopsies [33], 
microvascular obstruction measured with an Orthogo-
nal Polarization Spectral device in the rectal mucosa [46] 
or rosetting as determined by IgG antibody levels to the 
infected erythrocyte surface of ex vivo isolates and cor-
rected for disease severity [49]. Parasite biomass, as 
measured by PfHRP2, was correlated with Ang-2 in P. 
falciparum [34, 43, 46], but not as measured by PvLDH 
and pLDH in P. vivax. [43]. Three studies could not find 
a correlation between parasitaemia and Ang-1 and Ang-2 
in P. falciparum-infected children and adults [25, 33, 34]. 
However, three studies did observe a correlation between 
Ang-2 and the parasitaemia in P. falciparum- and P. 
vivax-infected children and adults [28, 43] or the Ang-2/
Ang-1 ratio [33]. Taken together, the relation between 
Ang-1 and Ang-2 and parasite abundance-related mark-
ers varies between the studies.
Aim II: Adjuvant therapy next to anti‑malarial treatment
Ang‑1 and Ang‑2 levels are influenced by anti‑inflammatory 
therapy
Ang-1 and Ang-2 concentrations have both been sug-
gested as adjuvant treatment targets in malaria [15, 53], 
but so far interventional studies in mice models or in 
humans have not been performed. Several studies used 
Ang-1 and Ang-2 as biomarkers for endothelial cell acti-
vation after an intervention aiming at another target.
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Adjuvant treatment strategies
In distinct studies, P. berghei (Anka strain)-infected mice 
and/or P. falciparum-infected humans received next to 
artesunate either a functional S1P receptor antagonist 
(FTY720 or LX2031 [38], a PPAR-γ agonist: rosiglitazone 
[26] or inhaled nitric oxide [40–42]. FTY720 and LX2931 
influence the homeostasis of inflammation and of vascu-
lar endothelium activity [54–56]. Rosiglitazone increases 
CD36-mediated phagocytosis of infected erythrocytes, 
has anti-inflammatory properties and improved sur-
vival in a cerebral malaria model previously [57, 58]. NO 
inhibits the exocytosis of Weibel–Palade bodies [59], 
organelles in endothelial cells that store both vWF and 
Ang-2. NO levels and cofactors required for NO synthe-
sis are known to be reduced during P. falciparum infec-
tion [34, 35, 44] and higher NO levels are associated with 
lower Ang-2 levels [34], whereas NO inhibitors positively 
correlate with Ang-2 [45]. Several processes contribut-
ing to the decreased NO levels during malaria have been 
studied, such as substrate limitation and increase in NO 
inhibitors [35], but these are beyond the scope of this 
review.
Adjuvant treatment in mice
No change in Ang-1 levels have been observed in mice 
treated with FTY720, one, three or five days after infec-
tion nor an increase in survival in treated mice three or 
five days after infection [38]. The survival rates also did 
not increase in both prophylactic and post-infection 
LX2931-treated mice. However, a higher Ang-1 concen-
tration and survival rate were observed in mice receiving 
prophylactic treatment with either FTY720 or iNO com-
pared to placebo-treated mice [38] (see Additional file 6). 
Survival rates increased in mice receiving adjuvant treat-
ment with rosiglitazone or iNO three or five days after 
infection compared to artesunate-only treated mice [40]. 
Rosiglitazone prevented the decrease in the Ang-1 con-
centration that was seen in mice treated only with artesu-
nate [26]. The Ang-2/Ang-1 mRNA levels, measured in 
homogenized brain tissue of mice, were significantly 
lower in mice prophylactically treated with iNO [40] or 
post-infectiously with rosiglitazone compared to mice 
treated only with artesunate [26]. These results demon-
strated an association between prophylactic therapy, 
decreased endothelium activation and increased survival 
rates.
When rosiglitazone was given to P. berghei-Anka-
infected mice with one Ang-1 allele deleted (Ang-1del), 
production of the Ang-1 levels was 30–50% compared 
to wild type mice five to six days post-infection [26]. 
An increase in survival was only seen in wild type mice 
treated with rosiglitazone and not in the Ang-1del mice 
treated with rosiglitazone [26]. This emphasizes that 
proper Ang-1 production apparently increases survival in 
a direct or indirect way, and therefore, a role of Ang-1 in 
the pathogenesis during malaria is likely.
Adjuvant treatment in humans
iNO as adjuvant therapy for severe malaria and rosigli-
tazone for uncomplicated malaria was also studied in 
humans. In a total of 272 Ugandan children, adjuvant 
iNO was given in two studies with either nitrogen [42] or 
air [41] as placebo treatment. No significant differences 
in Ang-1, Ang-2 concentrations nor survival between 
the iNO-treated and placebo groups was found in either 
study. In rosiglitazone-treated patients the Ang-2/Ang-1 
ratio was significantly lower compared to patients receiv-
ing placebo, as measured three days after treatment was 
started and parasite clearance was significantly enhanced 
[26]. None of the patients died or was admitted to inten-
sive care in both the treatment and control groups.
Discussion
The role of Ang-1 and Ang-2 as biomarkers and possible 
therapeutic targets in severe malaria was evaluated in 
this systematic review. Decreased Ang-1 and increased 
Ang-2 concentrations seem to be valuable as biomarker 
for disease severity and survival. The role of Ang-1 and 
Ang-2 in follow-up of treatment effectiveness, as well as 
their role as future therapeutic targets, are promising, but 
further studies are warranted. Nonetheless, some discus-
sion points before use as biomarkers or therapeutic tar-
gets remain.
Ang‑1 and Ang‑2 as biomarkers for disease severity
Uncomplicated malaria versus severe malaria and cerebral 
malaria
The results indicate that the decreased Ang-1 and the 
increased Ang-2/Ang-1 ratio are robust biomarkers 
to distinguish uncomplicated malaria from cerebral 
malaria [25, 28, 29, 32]. However, it is easier to distin-
guish uncomplicated malaria from cerebral malaria by a 
rapid clinical examination procedure as defined by WHO 
(cerebral malaria: severe P. falciparum with coma (Glas-
gow coma scale <11, Blantyre coma score <3), or malaria 
with coma persisting  >30  min after a seizure). Never-
theless, Ang-1, Ang-2 and the Ang-2/Ang-1 ratio could 
be valuable markers if they can identify patients with 
uncomplicated malaria at risk for progressing to severe 
disease. The area under the receiver operating character-
istic (AUROC) for distinguishing uncomplicated malaria 
from severe malaria is 0.88 (p = 0.001) and the sensitiv-
ity and specificity are 86% (95% CI 71–94) and 85% (95% 
CI 77–92), respectively [28] (see Additional file  7). This 
AUROC is higher than for plasma lactate [0.67 (95 CI % 
0.57–0.75)] or parasitaemia [0.53 (95% CI 0.45–0.62] as 
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found in an endemic area [60] and the sensitivity higher 
than in non-immune travellers (67%) [61]. Although the 
discriminating power of Ang-1 levels is promising, con-
clusion should be drawn with caution, as only one study 
in children (N  =  193) evaluated the AUROC to distin-
guish uncomplicated malaria from severe malaria [28].
Survivors versus non‑survivors
Ang-1 and Ang-2 levels can be used to distinguish 
malaria disease severity states but prediction of out-
come might be of more clinical value. Several studies 
that focussed on clinical outcome demonstrated that 
the Ang-2 level predicted mortality as well as, or better 
than, lactate blood levels in adults and children in Asia 
and Africa with severe and cerebral malaria [27, 33, 34]. 
Additional prospective studies that evaluate Ang-1 and/
or Ang-2 as markers of disease progression and clinical 
outcome should be performed to confirm these results.
Cerebral malaria versus other febrile CNS‑affecting diseases
A marker other than parasitaemia to distinguish cer-
ebral malaria from ‘other diseases with involvement of 
the CNS’ might be useful in patients with parasitaemia, 
as asymptomatic mild parasitaemia is not uncommon 
in malaria-endemic areas [62, 63]. Direct and indirect 
ophthalmoscopy can be used for this if retinopathy is 
observed with certain malaria-specific characteristics, 
such as retinal whitening, vessel changes, retinal haem-
orrhages, and papilledema. This clinical procedure has a 
sensitivity of 95% and a specificity of 90% for diagnosing 
cerebral malaria [64]. The Ang-1 concentration and the 
Ang-2/Ang-1 ratio were found to be good discriminators 
between ‘cerebral malaria with retinopathy’ and ‘other 
diseases with involvement of the CNS’ (see Additional 
file  7). However, cerebral malaria with retinopathy is 
already a selected group within the total group of patients 
with cerebral malaria, and therefore, it might overesti-
mate the sensitivity and specificity to diagnose cerebral 
malaria. In addition, the group of patients that will bene-
fit from a marker for cerebral malaria (patients with mild 
parasitaemia and a non-malaria disease that involves the 
CNS), were not represented in both studies that inves-
tigated the capacity of angiopoetin levels to distinguish 
cerebral malaria from other diseases with involvement of 
the CNS as parasitaemia in the latter group was absent. 
Nevertheless, to evaluate whether Ang-1 and/or Ang-2 
levels can identify these patients might be of clinical 
value.
Treatment follow‑up
Early parameters that indicate whether treatment is 
effective in malaria patients are valuable as treatment 
regimens may be reconsidered when patients do not 
properly recover. In both humans [26, 29, 34, 36, 37, 42] 
and mice [26, 38–40] recovery from malaria and survival 
was associated with an increase in Ang-1 and decrease in 
Ang-2 level (see Additional files 3, 4, 5, 7). However, the 
threshold for an Ang-1 increase or Ang-2 decrease that 
reflects proper recovery was not investigated. Neither 
were Ang-1 and Ang-2 levels compared with other clini-
cal or laboratory indices, e.g., fever or parasite clearance, 
which would be of interest.
Variation between studies
Even though Ang-1 and Ang-2 concentrations could dis-
criminate between disease severity states during malaria, 
distinct studies found varying levels of sensitivity and 
specificity (see Additional file  7). This variation may 
be due to: (1) host-related factors, such as genetic dif-
ferences between study populations and differences in 
acquired immunity towards Plasmodium species infec-
tion between study populations; (2) pathogen-related 
factors, such as infections with different strains with 
inherently differences in pathogenicity; and, (3) envi-
ronment-related factors, such as differences in access to 
healthcare that may result in delayed diagnosis or delayed 
start of proper treatment. In addition, the methods by 
which Ang-1 and Ang-2 levels are determined are further 
developing and currently lack proper standardization. 
Additional investigations are required before conclusions 
on the varying levels can be drawn.
Ang‑1 and platelet activation
A lower Ang-1 level was found in healthy controls com-
pared to P. falciparum-infected patients in one study 
which collected blood in CTAD tubes [36]. These tubes 
contain the platelet-stabilizing agents citrate, theophyl-
line, adenosine, and dipyridamole, which together result 
in a nearly complete block of in vitro platelet activation 
[65, 66]. The studies determining Ang-1 in serum [32] 
or in venous blood (not further specified) [25] found a 
higher level of Ang-1 in healthy controls compared to 
P. falciparum-infected patients. In addition, other stud-
ies that determined Ang-1 in malaria patients found a 
negative correlation between Ang-1 and disease sever-
ity. It is remarkable that the only study using tubes that 
avoid in  vitro platelet activation found a higher level of 
Ang-1, which is stored in platelets and released upon 
activation, in patients than in healthy controls. Platelet 
activation may occur in  vivo during malaria as induc-
tion of coagulation is proven even in early malaria [67]. 
To exclude altered Ang-1 levels due to in  vitro platelet 
activation after blood collection, platelet-poor specimens 
are preferred to determine platelet activation in  vivo. 
11-dehydrothromboxane B2 is a breakdown product of 
thromboxane A2 that is produced in  vivo by activated 
Page 8 of 12de Jong et al. Malar J  (2016) 15:581 
platelets. Since 11-dehydrothromboxane B2 is excreted in 
urine, a specimen that is free of platelets, determination 
of 11-dehydrothromboxane B2 in urine samples may esti-
mate in vivo platelet activation most accurately [68].
Lack of consistent associations between Ang‑1, Ang‑2 
and the parasitaemia in Plasmodium falciparum
Even though Ang-1 and Ang-2 concentrations corre-
late with disease severity, the results of the correlation 
between Ang-1 or Ang-2 concentrations in P. falciparum 
infection and parasitaemia, sequestration or rosetting 
vary between the studies [25, 28, 33, 34, 43, 46, 49]. The 
lack of a consistent correlation of the Ang-1 concentra-
tion, Ang-2 concentration and Ang-2/Ang-1 ratio with 
parasitaemia may be due to the fact that this parameter 
is determined in peripheral blood and does not reflect 
the true parasite load as sequestered parasites are not 
adequately taken into account. A correlation between 
PfHRP2, which reflects total parasite load during P. fal-
ciparum infection and Ang-2 was found in three studies 
[34, 43, 46], but sequestration [46] and rosetting cor-
rected for disease severity [49] did not correlate with 
Ang-1 and/or Ang-2 concentrations. The correlation 
between Ang-2 with parasite load but not with seques-
tration and rosetting might be due to: (1) the fact that 
PfHRP2 levels [34, 43, 46], measuring sequestration with 
a OPD device [46] and IgG antibody levels [49] are all 
markers that may not estimate their biological phenom-
ena similarly; (2) a temporal dissociation of the determi-
nations [46]; (3) loss of correlation due to the fact that 
locally observed phenomena (sequestration and roset-
ting) were compared to a systemic phenomenon (Ang-2 
release) [46]; or, (4) the infected erythrocytes may acti-
vate endothelial cells not by direct, physical contact, 
but indirectly by inducing other endothelial cell activa-
tors, such as cytokines [69, 70]. Next to the quantity of 
parasite biomass, the Plasmodium strain and the host 
response might contribute to the variations in Ang-2 
increase, although it should be noted that an included 
study [49] did not show a relation between Ang-2 and 
group A-like PfEMP expression if corrected for disease 
severity. However, the possible differences in other genes 
were not examined in that study. Taken together, the 
host-response-related marker Ang-2 might be a good or 
better biomarker for disease severity and treatment fol-
low-up than pathogen-related markers, such as parasite 
load or parasitaemia.
Ang‑2 in vivax versus falciparum malaria
Data on Ang-2 levels in P. vivax and P. falciparum dif-
fered between distinct studies: two studies found a higher 
Ang-2 level in P. falciparum compared to P. vivax [43, 
47] and one study found a higher Ang-2 level in P. vivax 
compared to P. falciparum [48]. However, comparison 
should be done with caution as these studies were per-
formed in different populations: patients in endemic 
areas [43, 47] versus travellers in non-endemic regions 
[48] and the parasitaemia was not reported in all stud-
ies [48]. In addition, the blood samples of P. vivax and 
P. falciparum of infected Canadian travellers were pro-
cessed differently [48], which may have influenced the 
Ang-2 levels results. Higher Ang-2 levels in P. vivax com-
pared to P. falciparum are plausible as P. vivax is known 
to induce a stronger cytokine response [4], which was 
also shown in an included study in adults in an endemic 
area [47]. These cytokines might contribute to endothe-
lial cell activation and therefore to Ang-2 release from 
Weibel–Palade bodies. Interestingly, in P. vivax-infected 
patients Ang-2 levels did not correlate with pLDH and 
PvLDH, which were proposed as markers that take 
both peripheral and hidden parasite load into account. 
Instead, a correlation was found between Ang-2 levels 
and parasitaemia. This might suggest a cytokine-inde-
pendent endothelial cell activation, as both hidden and 
peripheral-infected erythrocytes should contribute to the 
induction of the cytokine response. On the other hand, 
pLDH and PvLDH are not as well-established mark-
ers for the parasite biomass in P. vivax-infected patients 
[71] as PfHRP2 is in P. falciparum-infected patients, and 
therefore, no firm conclusions can be drawn yet. Addi-
tional research is necessary to elucidate the differences in 
pathogenesis between vivax and falciparum malaria and 
the role of endothelium activation during both Plasmo-
dium infections.
Clinical implementation
Although Ang-1 and Ang-2 levels can be used to dif-
ferentiate between disease severity states in malaria 
disease and might predict disease progression, their use 
in routine clinical practice is not yet possible. Malaria 
disease mainly occurs in resource-poor settings where 
it is not possible to determine Ang-1 or Ang-2 with 
complex laboratories techniques. If Ang-1 and Ang-2 
are shown to be robust biomarkers for disease pro-
gression, new simple rapid-point-of-care tests need to 
be developed for clinical use, as was done before for 
CRP [72] and for multiple haematological, biochemi-
cal and coagulation parameters [73]. Furthermore, the 
clinical consequences of a marker for disease progres-
sion are currently limited as no adjuvant treatment is 
yet available, next to medication, to eradicate the para-
site. However, development of adjuvant treatment and 
biomarkers to indicate which patients should receive 
adjuvant treatment go hand-in-hand and multiple adju-
vant treatment strategies are currently investigated (as 
reviewed by [74, 75]).
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The possible role of Ang‑1 and Ang‑2 in adjuvant 
treatment regimens for falciparum malaria
Studies using Ang-1 or Ang-2 as therapeutic target were 
only performed in sepsis, which shares many similarities 
with severe malaria caused by a P. falciparum infection. 
Both sepsis and malaria are characterized by cytokines 
release, coagulation alterations and endothelial cell acti-
vation [15, 18, 23]. In sepsis, Ang-1 was the mostly stud-
ied angiopoietin in interventional murine models (as 
reviewed by [24]). Ang-1 was found to be protective in 
endotoxin-induced shock or hyperoxia-induced lung 
injury models. However, most studies used Ang-1 treat-
ment prior to infection, which is not useful in a clinical 
setting for sepsis nor for malaria. Some of the studies 
giving Ang-1 after development of sepsis or acute lung 
injury found no reduction in mortality while others 
reported a positive effect [24]. In addition, it should be 
noted that P. berghei ANKA-infected CB57BL/6 mice, 
which are widely used as a model for human cerebral 
malaria, do show histopathological features that dif-
fer substantially from cerebral malaria in humans. 
Human cerebral malaria is characterized by sequestra-
tion, whereas inflammation is central in murine cer-
ebral malaria and the amount of sequestration limited 
[76]. These differences may contribute to the contrast-
ing results in outcome between iNO-treated, P. berghei 
ANKA-infected mice and P. falciparum-infected humans. 
This is supported by the observation that most success-
ful interventions in murine cerebral malaria show no 
significant effect in human cerebral malaria (as reviewed 
by [77]). More investigations on the therapeutic effect of 
post-infection use of Ang-1 in different disease models 
are needed before solid conclusions about the therapeu-
tic properties of Ang-1 and/or Ang-2 can be drawn.
The complexity of the host response to Plasmodium 
species infections possibly plays a role in the lack of effect 
of adjuvant treatment when given post infection. During 
malaria disease in humans and mice the immune system, 
coagulation system and the activity of endothelial cell are 
all systematically altered. These processes are complex 
and interweaved with each other (see Fig.  2). Providing 
even multi-targeted adjuvant treatment with FTY720 
or iNO at the moment that these regulatory systems 
are already systemically activated and upregulating each 
other may have too limited an effect to halt these feed-
forward stimulated processes. Multi-targeted adjuvant 
treatment, such as rosiglitazone, that (unlike FTY720 or 
iNO) was found to have an effect on Ang-1 and Ang-2 
levels and survival when administered post-infection, 
may however interfere with all the distinct regulatory 
systems in a way that reduces morbidity and mortality 
[26] (see Fig.  2), although further studies are definitely 
needed.
Conclusion
Ang-1 and Ang-2 concentrations correlate with disease 
severity and survival in malaria and show a good discrim-
inative power to distinguish disease severity states with 
predictive values equal to, or higher than, the currently 
used biomarkers plasma  lactate and parasitaemia. How-
ever, different disease severity states were compared in 
the distinct studies and not every distinction has clinical 
impact. The possible ability of Ang-1 and Ang-2 concen-
trations to distinguish cerebral malaria from other febrile 
CNS-affecting diseases and to predict those patients pro-
gressing from uncomplicated malaria towards severe 
malaria will have clinical value and should be studied in 
more detail before it can be used in routine practice.
For further optimization of treatment of patients with 
severe disease, multi-targeted adjuvant treatment regi-
mens are needed. Agents interfering with Ang-1 and or 
Ang-2 may be included in such adjuvant therapy as their 
Fig. 2 Interactions between different regulatory systems and the effects of therapeutics on the determinants. Coagulation, endothelial cell activa-
tion and immune system activation are processes that stimulate each other. FTY730, LX2931 and NO inhibit the immune system activation and 
endothelial cell activation. Rosiglitazone inhibits immune system activation, endothelial cell activation and upregulates CD36, which results in 
increased phagocytosis of the infected erythrocytes
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role as therapeutic target is promising. However, it is 
conceivable that agents interfering with multiple path-
ways are necessary, since multiple regulatory systems are 
consecutively activated during malaria infection.
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